Should I buy or sell Artelo Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Artelo Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARTL shares. View ARTL analyst ratings or view top-rated stocks .

What is Artelo Biosciences' stock price target for 2024?

1 analysts have issued twelve-month price objectives for Artelo Biosciences' shares. Their ARTL share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 280.2% from the stock's current price. View analysts price targets for ARTL or view top-rated stocks among Wall Street analysts .

How have ARTL shares performed in 2024?

Artelo Biosciences' stock was trading at $1.40 at the beginning of the year. Since then, ARTL stock has decreased by 6.1% and is now trading at $1.3150. View the best growth stocks for 2024 here .

Are investors shorting Artelo Biosciences?

Artelo Biosciences saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 14,500 shares, a drop of 28.2% from the March 15th total of 20,200 shares. Based on an average trading volume of 16,800 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.5% of the company's stock are sold short. View Artelo Biosciences' Short Interest .

When is Artelo Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ARTL earnings forecast .

How were Artelo Biosciences' earnings last quarter?

Artelo Biosciences, Inc. (NASDAQ:ARTL) announced its quarterly earnings results on Monday, March, 25th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.70.

When did Artelo Biosciences' stock split?

Artelo Biosciences's stock reverse split on Wednesday, August 10th 2022. The 1-15 reverse split was announced on Wednesday, August 10th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Artelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Artelo Biosciences investors own include NVIDIA (NVDA) , VBI Vaccines (VBIV) , Provention Bio (PRVB) , Sorrento Therapeutics (SRNE) , ADMA Biologics (ADMA) , Flexion Therapeutics (FLXN) , OPKO Health (OPK) , Overstock.com (OSTK) , Allena Pharmaceuticals (ALNA) and Advanced Micro Devices (AMD) .

How do I buy shares of Artelo Biosciences?

Shares of ARTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ARTL

Artelo Biosciences (ARTL) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free ARTL Stock Alerts

$1.32

+0.03 (+2.33%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.28
▼
$1.39
50-Day Range: $1.28
▼
$1.73
52-Week Range: $1.15
▼
$2.98

Volume: 5,512 shs
Average Volume: 16,092 shs
Market Capitalization: $4.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Get Artelo Biosciences alerts:

Artelo Biosciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 280.2% Upside
$5.00 Price Target
Short Interest: Healthy
0.45% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.07) to ($1.59) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.17 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Artelo Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Artelo Biosciences has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.45% of the float of Artelo Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Artelo Biosciences has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Artelo Biosciences has recently decreased by 28.22%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Artelo Biosciences does not currently pay a dividend.
Dividend Growth
Artelo Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ARTL.

0.6

News and Social Media Coverage

Search Interest
3 people have searched for ARTL on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Artelo Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Artelo Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.90% of the stock of Artelo Biosciences is held by insiders.
Percentage Held by Institutions
Only 0.87% of the stock of Artelo Biosciences is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Artelo Biosciences are expected to grow in the coming year, from ($2.07) to ($1.59) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Artelo Biosciences is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Artelo Biosciences is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Artelo Biosciences has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Artelo Biosciences Stock (NASDAQ:ARTL)

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

ARTL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ARTL Stock News Headlines

March 25, 2024 | benzinga.com

Recap: Artelo Biosciences Q4 Earnings

March 25, 2024 | msn.com

Artelo Biosciences GAAP EPS of -$3.14 misses by $0.58

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 25, 2024 | globenewswire.com

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

March 12, 2024 | globenewswire.com

Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge

February 15, 2024 | finanznachrichten.de

Artelo Biosciences, Inc.: Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th

January 8, 2024 | finance.yahoo.com

Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12

December 5, 2023 | finance.yahoo.com

Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

November 16, 2023 | markets.businessinsider.com

Promising Developments in Artelo Biosciences’ Cancer Therapies Drive Buy Rating Recommendation

November 13, 2023 | msn.com

Artelo Biosciences GAAP EPS of -$0.83 misses by $0.18

November 13, 2023 | finance.yahoo.com

Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

November 7, 2023 | morningstar.com

Artelo Biosciences Inc ARTL

November 2, 2023 | finance.yahoo.com

Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023

September 5, 2023 | finance.yahoo.com

Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th

August 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR), Artelo Biosciences (ARTL) and Unity Biotechnology (UBX)

June 28, 2023 | markets.businessinsider.com

Artelo Biosciences (ARTL) Receives a Buy from Ladenburg Thalmann & Co.

June 27, 2023 | msn.com

Artelo Unvails New Data On ART26.12 Demonstrating Positive Effects In Multiple Models Of Neuropathic Pain

June 27, 2023 | finance.yahoo.com

Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium

May 18, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Artelo Biosciences (ARTL), Iterum Therapeutics (ITRM) and TScan Therapeutics (TCRX)

May 11, 2023 | msn.com

Artelo Biosciences: Q1 Earnings Insights

May 11, 2023 | finance.yahoo.com

Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

April 25, 2023 | finance.yahoo.com

Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

April 4, 2023 | markets.businessinsider.com

Artelo Biosciences (ARTL) Gets a Buy from Maxim Group

April 3, 2023 | markets.businessinsider.com

Artelo Biosciences (ARTL) Gets a Buy from Ladenburg Thalmann & Co.

April 2, 2023 | seekingalpha.com

Artelo Biosciences GAAP EPS of -$3.56

February 15, 2023 | finance.yahoo.com

Artelo Biosciences to Present at MicroCap Rodeo’s Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 22, 2023

See More Headlines

Receive ARTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 1/12/2022
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ARTL
CUSIP: N/A
CIK: 1621221
Web: www.artelobio.com
Phone: (858) 925-7049
Fax: N/A
Employees: 5
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $5.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +280.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.14)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,290,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -61.68%
Return on Assets: -58.15%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.51
Quick Ratio: 8.51

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.12 per share
Price / Book: 0.32

Miscellaneous

Outstanding Shares: 3,230,000
Free Float: 3,005,000
Market Cap: $4.25 million
Optionable: Not Optionable
Beta: 1.45

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Gregory D. Gorgas M.B.A. (Age 61)
President, CEO, CFO, Treasurer, Secretary & Director
Comp: $654.83k
Dr. Andrew Yates Ph.D.
Senior VP & Chief Scientific Officer
Dr. Steven D. Reich (Age 78)
Chief Medical Officer
Mr. Jason H. Baybutt (Age 52)
Senior Vice President of Finance

Key Competitors

View All Competitors

ARTL Stock Analysis - Frequently Asked Questions

Should I buy or sell Artelo Biosciences stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Artelo Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARTL shares.
View ARTL analyst ratings or view top-rated stocks.
What is Artelo Biosciences' stock price target for 2024?: 1 analysts have issued twelve-month price objectives for Artelo Biosciences' shares. Their ARTL share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 280.2% from the stock's current price.
View analysts price targets for ARTL or view top-rated stocks among Wall Street analysts.
How have ARTL shares performed in 2024?: Artelo Biosciences' stock was trading at $1.40 at the beginning of the year. Since then, ARTL stock has decreased by 6.1% and is now trading at $1.3150.
View the best growth stocks for 2024 here.
Are investors shorting Artelo Biosciences?: Artelo Biosciences saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 14,500 shares, a drop of 28.2% from the March 15th total of 20,200 shares. Based on an average trading volume of 16,800 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.5% of the company's stock are sold short.
View Artelo Biosciences' Short Interest.
When is Artelo Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ARTL earnings forecast.

How were Artelo Biosciences' earnings last quarter?: Artelo Biosciences, Inc. (NASDAQ:ARTL) announced its quarterly earnings results on Monday, March, 25th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.70.
When did Artelo Biosciences' stock split?: Artelo Biosciences's stock reverse split on Wednesday, August 10th 2022. The 1-15 reverse split was announced on Wednesday, August 10th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Artelo Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Artelo Biosciences investors own include NVIDIA (NVDA), VBI Vaccines (VBIV), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Flexion Therapeutics (FLXN), OPKO Health (OPK), Overstock.com (OSTK), Allena Pharmaceuticals (ALNA) and Advanced Micro Devices (AMD).
How do I buy shares of Artelo Biosciences?: Shares of ARTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARTL) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial